Australia markets closed
  • ALL ORDS

    7,256.70
    -9.90 (-0.14%)
     
  • ASX 200

    7,056.20
    -9.00 (-0.13%)
     
  • AUD/USD

    0.6427
    +0.0010 (+0.16%)
     
  • OIL

    90.16
    +0.53 (+0.59%)
     
  • GOLD

    1,944.10
    +4.50 (+0.23%)
     
  • Bitcoin AUD

    41,477.17
    -594.64 (-1.41%)
     
  • CMC Crypto 200

    567.77
    -8.49 (-1.47%)
     
  • AUD/EUR

    0.6032
    +0.0019 (+0.31%)
     
  • AUD/NZD

    1.0819
    +0.0008 (+0.07%)
     
  • NZX 50

    11,372.62
    +53.88 (+0.48%)
     
  • NASDAQ

    14,694.24
    -275.68 (-1.84%)
     
  • FTSE

    7,678.62
    -53.03 (-0.69%)
     
  • Dow Jones

    34,070.42
    -370.46 (-1.08%)
     
  • DAX

    15,571.86
    -209.73 (-1.33%)
     
  • Hang Seng

    17,902.04
    +246.63 (+1.40%)
     
  • NIKKEI 225

    32,402.41
    -168.62 (-0.52%)
     

Why Shares of Ocular Therapeutix Jumped This Week

Why Shares of Ocular Therapeutix Jumped This Week

Shares of Ocular Therapeutix (NASDAQ: OCUL) were up by 49.6% for the week as of Thursday's market close, according to data provided by S&P Global Market Intelligence. The biopharmaceutical company specializes in finding therapies to treat diseases and conditions of the eye. The healthcare company, on Feb. 11, announced preliminary 10-month data on its phase 1 trial of OTX-TKI, an axitinib (a small molecule, multitarget, tyrosine kinase inhibitor) intravitreal (inside the eye) hydrogel implant to treat age-related macular degeneration (AMD), diabetic retinopathy and other diseases of the retina.